Therapeutic drug monitoring of infliximab in spondyloarthritis. A review of the literature. [PDF]
Br J Clin Pharmacol, 2019 Fobelo Lozano MJ +2 more
europepmc +1 more source
Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States? [PDF]
BioDrugs, 2020 Alvarez DF +4 more
europepmc +1 more source
Biosimilars: Review of current applications, obstacles, and their future in medicine. [PDF]
World J Clin Cases, 2018 Kaida-Yip F +3 more
europepmc +1 more source
Real-World Effectiveness and Safety of Infliximab Biosimilar CT-P13 for Rheumatic Diseases: A National Observational Cohort Study (ReFLECT). [PDF]
Adv TherMarotte H +7 more
europepmc +1 more source
Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases. [PDF]
Therap Adv Gastroenterol, 2016 Sieczkowska J +4 more
europepmc +1 more source
, 2017 Specyfikę cywilizacji indyjskiego subkontynentu uwypuklają wielojęzykowość i wieloetniczność. Przyrastały od zamierzchłej przeszłości i dziś tworzą problemy.
openaire +1 more source
Insights on the use of biosimilars in the treatment of inflammatory bowel disease. [PDF]
World J Gastroenterol, 2017 Zheng MK, Shih DQ, Chen GC.
europepmc +1 more source
Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. [PDF]
Eur J Health Econ, 2014 Baji P +6 more
europepmc +1 more source